NASDAQ:NERV - Minerva Neurosciences Stock Price, Forecast & News

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

Minerva Neurosciences Inc (NASDAQ:NERV) issued its earnings results on Monday, November, 4th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.37) by $0.01. View Minerva Neurosciences' Earnings History.

Minerva Neurosciences is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Minerva Neurosciences.

4 equities research analysts have issued 12-month price targets for Minerva Neurosciences' stock. Their forecasts range from $17.00 to $26.00. On average, they anticipate Minerva Neurosciences' stock price to reach $20.25 in the next year. This suggests a possible upside of 132.2% from the stock's current price. View Analyst Price Targets for Minerva Neurosciences.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Minerva Neurosciences.

News articles about NERV stock have trended very negative on Tuesday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Minerva Neurosciences earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Minerva Neurosciences.

Minerva Neurosciences saw a decrease in short interest in January. As of January 15th, there was short interest totalling 3,100,000 shares, a decrease of 16.9% from the December 31st total of 3,730,000 shares. Based on an average trading volume of 406,100 shares, the short-interest ratio is presently 7.6 days. Currently, 9.6% of the shares of the company are short sold. View Minerva Neurosciences' Current Options Chain.

Some companies that are related to Minerva Neurosciences include IGM Biosciences (IGMS), Y-mAbs Therapeutics (YMAB), Intra-Cellular Therapies (ITCI), Supernus Pharmaceuticals (SUPN), Rocket Pharmaceuticals (RCKT), Athenex (ATNX), Revance Therapeutics (RVNC), Phibro Animal Health (PAHC), Endonovo Therapeutics (ENDV), NextCure (NXTC), Portola Pharmaceuticals (PTLA), Myovant Sciences (MYOV), Opko Health (OPK), Akebia Therapeutics (AKBA) and Enanta Pharmaceuticals (ENTA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include PTC Therapeutics (PTCT), Inovio Pharmaceuticals (INO), Immunomedics (IMMU), Exelixis (EXEL), Melinta Therapeutics (MLNT), Progenics Pharmaceuticals (PGNX), Synergy Pharmaceuticals (SGYP), Anavex Life Sciences (AVXL), Cara Therapeutics (CARA) and Amicus Therapeutics (FOLD).

Minerva Neurosciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (5.19%), Renaissance Technologies LLC (1.92%), State Street Corp (1.46%), Jacobs Levy Equity Management Inc. (0.96%), J. Goldman & Co LP (0.64%) and Point72 Asset Management L.P. (0.58%). Company insiders that own Minerva Neurosciences stock include David Kupfer, Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Remy Luthringer, Richard E Russell, Venture Associates L Index III and William F Doyle. View Institutional Ownership Trends for Minerva Neurosciences.

NERV stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, State Street Corp, Bank of New York Mellon Corp, Bank of America Corp DE, Connor Clark & Lunn Investment Management Ltd., Goldman Sachs Group Inc. and TD Asset Management Inc.. Company insiders that have sold Minerva Neurosciences company stock in the last year include Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Remy Luthringer and Venture Associates L Index III. View Insider Buying and Selling for Minerva Neurosciences.

NERV stock was bought by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., J. Goldman & Co LP, Barclays PLC, Point72 Asset Management L.P., Acadian Asset Management LLC, Russell Investments Group Ltd., Renaissance Technologies LLC and California Public Employees Retirement System. Company insiders that have bought Minerva Neurosciences stock in the last two years include David Kupfer and William F Doyle. View Insider Buying and Selling for Minerva Neurosciences.

Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NERV stock can currently be purchased for approximately $8.72.

Minerva Neurosciences has a market capitalization of $340.34 million. The biopharmaceutical company earns $-50,170,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. Minerva Neurosciences employs 13 workers across the globe.View Additional Information About Minerva Neurosciences.

The official website for Minerva Neurosciences is http://www.minervaneurosciences.com/.

Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-600-7373 or via email at [email protected]